PD-L1是目前NSCLC免疫治疗最重要的疗效预测指标[1]。EGFR突变肺癌PD-L1蛋白表达波动范围较大,阳性率11%-73%不等[14-16]。EGFR突变肺癌PD-L1表达水平增高、还是降低,不同研究结果不一致,甚至彼此矛盾。. The gene discussed is CD274; the disease is non-small cell lung carcinoma.